We believe our findings lay a framework for an immune-mediated strategy for treating aggressive breast cancer subtypes (TNBC and HER2+ breast cancer), by co-administration of Ad-HER3 with HER2-targeted or EGFR-targeted therapies. This evidence concerns the gene EGFR and breast carcinoma.